When it comes to pricing Sovaldi, how NICE of them

By Merrill Goozner  |  March 17, 2015

New cost-effectiveness analyses of Sovaldi and other treatments to treat chronic hepatitis C infection suggest U.S. firms initially set prices near the ceiling that the United Kingdom's National Health Service will pay for drugs.

Study weighs debt financing for pricey breakthrough drugs

By Steven Ross Johnson  |  March 11, 2015

The emergence of new specialty breakthrough medications has come with a hefty price tag that may demand alternative financing approaches to ensure they remain accessible to patients, a new analysis suggests.

The high price of precision medicine

The high price of precision medicine

By By  |  March 07, 2015

Financial markets have sent another signal that the coming era of precision or personalized medicine could wind up making cancer care unaffordable for millions of people.

Q&A: 'Imagine if healthcare were priced to consumers'

Q&A: 'Imagine if healthcare were priced to consumers'

By Modern Healthcare  |  February 14, 2015

Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.

Hep C drug price war likely to slow Gilead’s growth

By By  |  February 06, 2015

The soaring sales and profits reported by Gilead Sciences in 2014 aren't likely to be repeated as the company begins to offer steeper discounts on its blockbuster hepatitis C treatments Sovaldi and Harvoni.

Gilead's 2014 profit margin nears 50%, fueled by hep C drugs

By By  |  February 03, 2015

Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.

Gilead promotes two to executive VP

By Adam Rubenfire  |  February 03, 2015

Gilead Sciences, the biopharmaceutical company, announced the promotion of two employees to executive vice president positions. Dr. Andrew Cheng has been promoted to executive VP of HIV therapeutics and development operations, and Taiyin Yang has been promoted to executive VP of pharmaceutical...

Insurers eye pharma discounts beyond hepatitis C

By Bob Herman  |  February 02, 2015

The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.

Tamiflu controversy reignited by new study

By Sabriya Rice  |  January 29, 2015

The antiviral medication Tamiflu shortened the length of time patients experienced flu symptoms, and reduced rates of complications and hospitalizations from the virus, a new study finds. But it did not have an effect on those with flu-like symptoms who did not have the flu.

Obamacare legal challenge downplayed by business leaders

Obamacare legal challenge downplayed by business leaders

By Bob Herman  |  January 17, 2015

The nation's largest healthcare organizations predicted a profitable 2015 at the annual J.P. Morgan Healthcare Conference in San Francisco. They forecast that the biggest cloud on the horizon—the pending U.S. Supreme Court case challenging the Obamacare premium subsidies—would pass...

Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.